Vas Narasimhan

Novartis' cholesterol buster, new trials fall victim to COVID-19

Novartis stopped enrolling patients in a trial of its cholesterol fighter inclisiran even as it expects its trials to stay on course in the long term.

Amirah Al Idrus Apr 28, 2020 10:40am